What drove AYA.AX stock lower today?

AYA.AX stock fell **8.29%** on 28 Jan 2026 after intraday profit-taking amid overbought technical indicators (RSI **70.89**) and ongoing negative earnings. Traders trimmed positions ahead of the 24 Feb 2026 earnings announcement.

What is Meyka AI's forecast for AYA.AX stock?

Meyka AI's forecast model projects AYA.AX at **A$7.30** in 12 months, implying roughly **88.73%** upside from **A$3.87**. Forecasts are model-based projections and not guarantees.

Is AYA.AX stock a profitable company today?

No. Artrya reports a trailing EPS of **-0.18** and negative operating cash flow per share. The company is investing heavily in R&D as it scales Salix in clinical markets.

What are the main risks for AYA.AX stock?

Main risks for AYA.AX stock include slow clinical adoption, persistent losses, high R&D burn, and valuation compression if revenue growth lags. Regulatory or contract setbacks would also weigh on the share price.

AU Stocks

AYA.AX down 8.29% to A$3.87 Artrya Limited (ASX) market closed 28 Jan 2026: AI stocks outlook

ByHuzaifa Zahoor January 28, 2026January 28, 2026

AYA.AX stock closed the session at A$3.87, down 8.29% on 28 Jan 2026 after a volatile day that saw a high of A$4.12 and low of A$3.79. Traders reacted to a mix of technical overbought signals and company fundamentals. Artrya Limited (AYA.AX) remains a small-cap Australian medtech focused on AI coronary disease detection. We summarise price action, financial metrics, technicals, Meyka AI grading and a model forecast to frame the near-term AI stocks outlook for AYA.AX stock.